A Phase II Study of Bevacizumab, Irinotecan, and Temozolomide for Relapsed or Refractory Neuroblastoma
[Protocol 10-015] |
Modak, Shakeel |
|
A Phase Ib Study of Trastuzumab-MCC-DM1, Paclitaxel, and Pertuzumab in Patients with HER2-Positive, Locally Advanced or Metastatic Breast Cancer Who Previously Received Trastuzumab
[Protocol 09-093] |
Modi, Shanu |
|
A Phase IB Study of SGN-75 plus Everolimus in Patients with CD70-Positive Metastatic Renal Cell Cancer
[Protocol 12-263] |
Molina, Ana Maria |
|
A Phase IB/II study of E7080 plus Everolimus in Patients with Unresectable Advanced/Metastatic Renal Cell Carcinoma
[Protocol 10-084] |
Molina, Ana Maria |
|
A Phase II Trial of Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Cancer
[Protocol 10-226] |
Molina, Ana Maria |
|
A Phase I Study of AGS-16C3F in Patients with Clear Cell or Papillary Renal Cell Cancer
[Protocol 12-162] |
Molina, Ana Maria |
|
Radium-223 (Alpharadin) in Men with Castration-Resistant Prostate Cancer and Bone Metastases
[Protocol 12-199] |
Morris, Michael |
- Prostate Cancer
- Metastatic Disease after Hormone-Reducing Therapy
|
A Phase I Study of ASG-5ME Therapy Patients with Advanced Prostate Cancer
[Protocol 10-138] |
Morris, Michael |
- Prostate Cancer
- Metastatic Disease after Hormone-Reducing Therapy
|
[18F]-Deoxy-D-Glucose (FDG) and [18F] Dihydro-Testosterone PET Imaging in Patients with Progressive Prostate Cancer
[Protocol 00-095] |
Morris, Michael |
- Prostate Cancer
- Metastatic Disease after Hormone-Reducing Therapy
- Rising PSA After Primary Therapy
|
A Phase I/IIa Study of Alpharadin® Plus Docetaxel in Patients with Bone Metastases from Castration-Resistant Prostate Cancer
[Protocol 10-086] |
Morris, Michael |
- Prostate Cancer
- Metastatic Disease after Hormone-Reducing Therapy
|
Brentuximab (SGN-35) in Transplant-Eligible Patients with Relapsed or Refractory Hodgkin Lymphoma
[Protocol 11-142] |
Moskowitz, Alison |
|
A Phase III Study of KW-0761 versus Vorinostat in Patients with Previously Treated Cutaneous T-Cell Lymphoma
[Protocol 13-007] |
Moskowitz, Alison |
|
A Phase I Study of SGN-CD19A in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
[Protocol 12-282] |
Moskowitz, Craig |
|
Risk-Adapted Therapy for Patients With Untreated Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B-Cell Lymphoma
[Protocol 08-026] |
Moskowitz, Craig |
|
A Phase II Study of Everolimus as Second-Line Therapy in the Treatment of Metastatic Renal Cell Carcinoma
[Protocol 11-197] |
Motzer, Robert |
|
A Phase III Study of BMS-936558 Versus Everolimus in Patients with Advanced or Metastatic Renal Cell Carcinoma Who Received Prior Anti-Angiogenic Therapy
[Protocol 12-159] |
Motzer, Robert |
|
A Phase III Study of Pazopanib as Adjuvant Therapy for Patients with Localized or Locally Advanced Renal Cell Carcinoma Following Nephrectomy
[Protocol 10-162] |
Motzer, Robert |
|
A Randomized Trial of Pharmacological Penile Rehabilitation in the Preservation of
Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy
[Protocol 09-005] |
Mulhall, John |
- Prostate Cancer
- Survivorship
|
ICARuS (Intraperitoneal Chemotherapy After cytoReductive Surgery): A Phase II Study of Early Post-Operative Abdominal Chemotherapy versus Heated Abdominal Chemotherapy for Cancers of the Appendix, Colon, or Rectum that Have Spread to the Abdominal Lining
[Protocol 12-289] |
Nash, Garrett |
|
The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men with Prostate Cancer Age 65 and Older
[Protocol 06-084] |
Nelson, Christian |
- Geriatrics
- Prostate Cancer
- Localized Disease
- Quality of Life
- Rising PSA After Primary Therapy
- Psychiatry & Behavioral Sciences
- Survivorship
|
